Showing 3971-3980 of 5231 results for "".
- Acne-Specific Dermatology Platform Site Goes Livehttps://practicaldermatology.com/news/20130801-acne-specific_dermatology_platform_site_goes_live/2459485/
- AMA Foundation Awards Research Grants To Study Issues Affecting Women In Medicinehttps://practicaldermatology.com/news/20130521-ama_foundation_awards_research_grants_to_study_issues_affecting_women_in_medicine/2459535/In 1850, the first medical institution in the world established to train women in medicine and offer opportunities of an MD opened their doors in Philadelphia. For those women, it was a chance to enter the medical world that routinely shut them out. While women today don't face such a task, importan
- Onset Dermatologics Unveils Anti-Itch Gel for Eczemahttps://practicaldermatology.com/news/20130515-onset_unveils_anti-itch_gel_for_eczema/2459544/A new product for itching associated with eczema is now available from Onset Dermatologics. Aurstat® Anti-Itch Hydrogel is engineered to soothe itching, burning, and pain of atopic dermatitis and various dermatoses, according to the company. The patented hydrogel formulation is alcohol free, fragran
- Nuvo and Galderma Win FDA Approval for Topical Peelhttps://practicaldermatology.com/news/20121022-nuvo_and_galderma_win_fda_approval_for_topical_peel/2459699/Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval
- Physicians Report Health IT Growing But Systems Laghttps://practicaldermatology.com/news/20120921-physicians_report_health_it_growing_but_systems_lag/2459732/A new Optum Institute/Harris Interactive national survey provides insights into US consumers' willingness to view their medical records and engage with care providers online. The survey was conducted online within the United States among 1,000 US physicians, 2,870 US adults, and 400 US hospital exec
- Healthcare Spending Growth Expected to Remain Lowhttps://practicaldermatology.com/news/20120603-healthcare_spending_growth_expected_to_remain_low/2459793/
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://practicaldermatology.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Report: Skin Lightening Resurgence Raises Safety Concernshttps://practicaldermatology.com/news/report-skin-lightening-resurgence-raises-safety-concerns/2485703/A growing global resurgence in skin lightening (SL) practices is raising renewed safety and public health concerns, according to a recent publication in the Journal of the American Academy of Dermatology.